Drw Securities adds Lipocine Inc (LPCN) to its portfolio

Lipocine Inc (LPCN) : Drw Securities added new position in Lipocine Inc during the most recent quarter end. The investment management firm now holds 145,859 shares of Lipocine Inc which is valued at $653,448 , the company said in a statement filed on Aug 15, 2016 with the SEC.Lipocine Inc makes up approximately 0.20% of Drw Securities’s portfolio.

Other Hedge Funds, Including , Rhumbline Advisers added LPCN to its portfolio by purchasing 17,457 company shares during the most recent quarter which is valued at $78,207. Geduld E E added LPCN to its portfolio by purchasing 30,000 company shares during the most recent quarter which is valued at $126,900. Lipocine Inc makes up approx 0.18% of Geduld E E’s portfolio. Eam Investors sold out all of its stake in LPCN during the most recent quarter. The investment firm sold 369,314 shares of LPCN which is valued $1,366,462.

Lipocine Inc opened for trading at $3.41 and hit $3.49 on the upside on Thursday, eventually ending the session at $3.43, with a gain of 1.78% or 0.06 points. The heightened volatility saw the trading volume jump to 1,16,109 shares. Company has a market cap of $63 M.

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company’s primary development programs are based on oral delivery solutions for bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements bypass first-pass metabolism reduce side effects and eliminate gastrointestinal interactions that limit bioavailability. The Company’s lead product candidate LPCN 1021 is an oral testosterone replacement therapy (TRT) designed for twice-a-day dosing and is in Phase III testing. Additional pipeline candidates include LPCN 1111 an oral testosterone therapy product targeted for once daily dosing which is in Phase II testing and LPCN 1107 an oral therapy for the prevention of preterm birth which is in Phase I testing.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *